753B has been found to reverse chemotherapy-induced SnCs phenotype and induce death in senescent AML cells by increasing BCL-XL/BCL-2 expression, and to trigger time and dose-dependent BCL-XL degradation at concentrations lower than that of DT2216 [90,91]. This evidence concerns the gene BCL2 and acute myeloid leukemia.